Looking ahead to 2026: Trends and expectations for International Arbitration
Across both investor-state and commercial cases, quantum debates have recently turned on attribution under concurrent shocks, the interaction of contract terms...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s life sciences arbitration support is grounded in a comprehensive, insiders’ understanding of pharmaceutical, biotechnology, medical device, and diagnostic markets. For more than 25 years, we have consulted directly with major life science companies, law firms, and regulatory agencies around the globe. This deep industry knowledge is complemented by our extensive experience in complex litigation. CRA’s involvement has helped our clients solve their most challenging strategic problems and resolve their most contentious disputes.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comAcross both investor-state and commercial cases, quantum debates have recently turned on attribution under concurrent shocks, the interaction of contract terms...
Dear Clients and Friends, Our activities in 2024 reflected ongoing trends from 2023 and emerging forces affecting the landscape for investors and companies...





